ReviewAnnual review of pharmacology and toxicology2015
Novel targeted therapies for eosinophil-associated diseases and allergy.
Review in Annual review of pharmacology and toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Evidence of Inflammatory Network Disruption in Chronic Venous Disease: An Analysis of Circulating Cytokines and Chemokines.Biomedicines · 2025Article
- Childhood blood eosinophils and symptoms of allergic disorders: a cross-sectional study in Southern China.Annals of medicine · 2022Article
- Chronic Venous Disease during Pregnancy Causes a Systematic Increase in Maternal and Fetal Proinflammatory Markers.International journal of molecular sciences · 2022Article
- Regulation of eosinophil functions by autophagy.Seminars in immunopathology · 2021Review
- Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI.Scandinavian journal of immunology · 2021Review
- Eosinophils in skin diseases.Seminars in immunopathology · 2021Review
- Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.Seminars in immunopathology · 2021Review
- Apoptosis of Eosinophil Granulocytes.Biology · 2020Review
- The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020.International archives of allergy and immunology · 2020Review
- Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review.Drugs · 2019Review
- [Eosinophilic granulocytes-Physiology and pathophysiology].Zeitschrift fur Rheumatologie · 2019Review
- Regulation of the innate immune system by autophagy: neutrophils, eosinophils, mast cells, NK cells.Cell death and differentiation · 2019Review
- Eosinophilia and Kidney Disease: More than Just an Incidental Finding?Journal of clinical medicine · 2018Review
- Review
- Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.American journal of rhinology & allergy · 2018Review
- The eosinophil: For better or worse, in sickness and in health.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Review
- Biological therapies for eosinophilic gastrointestinal diseases.The Journal of allergy and clinical immunology · 2018Review
- Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid.The Journal of investigative dermatology · 2018Article
- Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples.Frontiers in immunology · 2018Article
- CD300f:IL-5 cross-talk inhibits adipose tissue eosinophil homing and subsequent IL-4 production.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.